Fosun Pharma (600196.SH) announced on Zhitong Finance APP that the listing registration application for the injection of nicorandil ("the new drug"), independently developed by its controlled subsidiary Chongqing Pharmafriend Pharmaceutical Co., Ltd. for the treatment of unstable angina, has recently been approved by the National Medical Products Administration. According to IQVIA CHPA's latest data, the sales of nicorandil injections in China are expected to reach approximately RMB 785 million in 2023.
复星医药(600196.SH)：注射用尼可地尔用于治疗不稳定型心绞痛的上市注册申请获批
Fosun Pharma (600196.SH): The market registration application for injection nicorandil for the treatment of unstable angina has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.